Oligosaccharide Substrate and Inhibitor Interactions with beta-1,4-Gal-T1
Oligosaccharide Substrate and Inhibitor Interactions with beta-1,4-Gal-T1
批准号:
7965207
负责人:
Pradman K Qasba
金额:
$5.08万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AffinityBindingBinding SitesBiological ModelsBiological ProcessCanadaCarbohydratesCell AdhesionCell surfaceCellsChemicalsCollaborationsComplexDimerizationDisaccharidesEnzyme Inhibitor DrugsEnzyme InhibitorsEnzyme KineticsEnzymesEpitopesExhibitsFamily memberFocal Adhesion Kinase 1FutureGalactoseGalactosyltransferasesGlycoconjugatesGlycolipidsGlycoproteinsHomoHourHumanHydrogen BondingImmunoglobulin GIn VitroIntegrinsKineticsLeadLinkMannoseMass Spectrum AnalysisModificationMonoclonal AntibodiesMonosaccharidesNaphthaleneNaphthalenesNeoplasm MetastasisOligosaccharidesOntarioPatternPlayPolysaccharidesPositioning AttributeProteinsPublishingRoleSideSpecificityStructureTrisaccharidesTyrosine PhosphorylationUniversitiesUpper armUrsidae FamilyWateramino groupanalogcell growthchitobiosecrosslinkdesignflexibilityglycosyltransferasehuman diseasehydroxyl groupimprovedinhibitor/antagonistlactosaminelink proteinmanmutantpreferenceresponsesimulationtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
<P>Our previous crystallographic studies on b4Gal-T1 and of the mutant Met340His-b4Gal-T1 in complex with chitobiose and various trisaccharides, together with the enzyme kinetic analysis and MD simulations defined the oligosaccharide binding site of b4Gal-T1 (see Project #s Z01 BC 009304). For a better understanding of the branch specificity of b4Gal-T1 towards the GlcNAc residues of N-glycans, the kinetic and crystallographic studies with the wild-type human b4Gal-T1 (h-b4Gal-T1) and the mutant Met340His-b4Gal-T1 (h-M340H-b4Gal-T1), in complex with a GlcNAc containing pentasaccharide and several GlcNAc containing trisaccharides present in N-glycans, showed that b4Gal-T1 preferentially interacts with the 1,2-1,6-arm trisaccharide rather than with the 1,2-1,3-arm or 1,4-1,3-arm of a bi- or tri-antennary oligosaccharide chain of N-glycan (see 2006 project # Z01 BC 010041). Using synthetic trisaccharides as acceptor model systems, we showed that the acceptor 1,2-1,3-arm (GlcNAc-b1,2-Man-a1,3-Man) and 1,4-1,3-arm (GlcNAc-b1,4-Man-a1,3-Man) trisaccharides have a 10- to 60-fold higher Km for b4Gal-T1 than the 1,2-1,6-arm trisaccharide (GlcNAc-b1,2-Man-a1,6-Man), latter shows substrate inhibition at concentrations that are much lower than for other acceptor substrates.</p><P><i><b> Transfer preferences of b4Gal-T1 to the 1-3 or 1-6 arm of a biantennary glycan of IgG: </i></b>: We determined the transfer preferences of b4Gal-T1 to 1-3 or 1-6-arm of the biantennary glycan of IgG. Each heavy chain of IgG carries a complex bi-antennary N-linked glycan chain at Asn 297 in the Fc-region. These glycans show various glycosylated patterns; G0 glycoform having two terminal GlcNAc residues, and G1 and G2 glycoforms which bear oligosaccharides with one or two terminal galactose, respectively. We established the condition for the complete de-galactosylation (100 %) to G0 form for the studies on the transfer of galactose by b4Gal-T1. To establish which antenna, 1-3-arm or 1-6-arm, or both, of the N-linked glycan of IgG is galactosylated, we, in collaboration with Dr. Timothy Weybright (from Dr. Timothy Veenstras group, of the Mass Spectrometry Center, BPP, SAIC-Frederick, Inc.), analyzed the oligosaccharide products released after PNGaseF treatment of the monoclonal antibodies by MS/MS analysis. We established that after 6 hr transfer of galactose by the wild type b4al-T1 to G0 glycoform (MW 1485) of IgG, galactose is mainly transferred to one arm (G1 glycoform, MW 1647). Further MS/MS analysis of the bi-antennary glycan chain shows that the wild type b4Gal-T1transfers galactose at a faster rate to the GlcNAc attached to the Man 1-3 arm. In contrast, the mutant b4Gal-T1-Y289L at 6 hours incubation transfers GalNAc mainly to both arms (G2 glycoform MW 1891). MS/MS analysis of the G1 glycoform after PNGasesF treatment of the monoclonal antibodies show that the mutant Y289L- b4Gal-T1 transfers GalNAc at a faster rate to the GlcNAc attached to the Man 1-6 arm.</p> <P><i><b>Crystal structure of the h-M340H-Gal-T1 in complex with the disaccharide GlcNAc-b3Gal-b-O-napthalenemethanol </i></b>: A class of synthetic disaccharides has been shown as potential inhibitors of tumor metastasis by Dr. Jeff Eskos lab in UC, San Diego. They are high affinity substrates for b4GalT1 and thus act as decoys for the synthesis of sialyl Lewis X (sLeX ), the cell adhesion epitope, which is expressed at elevated levels in metastatic cells. The most effective compound they have identified to date is GlcNAc-b3Gal-b-O-napthalenemethanol. The acetylated compound is taken up by the cells, O-deacetylated, and then the disaccharide decoys the synthesis of sLeX-containing glycans on cell surface glycoconjugates. In several model systems this results in an inhibition of tumor formation. As Dr. Eskos lab has observed, all the activity of the compound depends on the action of b4GalT(s) in the cell, since the first step in its utilization involves galactosylation. In their in vitro studies with GlcNAc-b3Gal-b-O-napthalenemethanol as an acceptor substrate for b4Gal-T1, they show a Km of 10 &#956;M. This high affinity for the enzyme may be its unique mode of binding to b4Gal-T1 similar to the one we have observed with the 1,2-1,6-arm trisaccharide (see above). We have carried the crystal structure of h-M340H-Gal-T1 with GlcNAc-b3Gal-b-O-napthalenemethanol, provided by Dr. Eskos lab, and determined the mode of interaction between the disaccharide and the enzyme. The overall binding of GnGl-NP to the Met344His-Cys342Thr-Gal-T1 molecule is quite similar to the binding of the tri-saccharide GlcNAcb1-2Mana1-6Mana, observed earlier (see 2006 project # Z01 BC 010041), suggesting its Km for the enzyme will be similar to that of the 1-6 arm tri-saccharide, a Km of 60 &#956;M. This tri-saccharide is derived from the 1-6 arm of the biantennary N-glycan, starting from the core mannose to the free GlcNAc at the non-reducing end. In the enzyme-bound 1-6 arm tri-saccharide, the middle mannose exhibits the least interactions with the protein molecule, while the terminal mannose (i.e., the core mannose residue of the biantennary N-glycans) makes extensive stacking interactions with the aromatic side chain of the Tyr282 residue.In contrast, the beta-linked Gal residue in the disaccharide GnGl-NP forms extensive stacking interactions with Tyr282, and the terminal aromatic naphthalene residue makes additional interactions, although weak, in the oligosaccharide binding site of the b4Gal-T1 molecule. Therefore, due to the additional interactions that arise from the naphthalene moiety, it is expected that GnGl-NP disaccharide will have a lower Km than that of the 1-6 arm tri-saccharide, thus making it the best known acceptor substrate with the highest affinity for b4Gal-T1. Furthermore, the b4Gal-T family members T5 and T6 have the conserved residue Tyr corresponding to the Phe356 residue of the b4Gal-T1. The Tyr residue in these family members is expected to make additional hydrogen bonding interactions via the side-chain hydroxyl group of the Tyr residue, which is expected to further lower the Km of the GnGl-NP disaccharide for b4Gal-T5 and b4Gal-T6. From the crystal structure analysis we are able to understand the high affinity of the disaccharide GnGl-NP for b4Gal-T1. Furthermore, these analysis suggested that future chemical modifications, such as incorporating the structural water molecule in the acceptor design, amino or methylated amino group at the second position of Gal or even appropriate substitutions of polar groups at the naphthalene ring, may improve the affinity of the acceptor substrate and lead to better design of the disaccharide inhibitors for the tumor metastasis. These results have been published in J. Biol. Chem. 2009, 284, 4952-4959.</p><P><i><b>Crystal structure of the h-M340H-Gal-T1 in complex with the 1-thio-N-butyryl GlcN-beta-(2-naphthyl)</i></b>:Several compounds having a bicyclic structures namely 2-naphthyl aglycones have been found by Dr. Inka Brockhausen (Queens University, Kingston, Ontario, Canada), to bind and inhibit the activity of b4Gal-T1. The best small hydrophobic GlcNAc-analog inhibitor that they have found is 1-thio-N-butyral-GlcN-beta-(2-naphthyl) with a Ki of 40 &#956;M. This high affinity for the enzyme may be its unique mode of binding to b4Gal-T1 similar to the one we have observed with the 1,2-1,6-arm [summary truncated at 7800 characters]
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structural Studies and 3D Structure Determination of Recombinant <FONT FACE=symb
-
批准号:6433157
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Oligosaccharide Interactions with Proteins
-
批准号:6559116
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Oligosaccharide substrate interactions with beta-1,4-Ga
-
批准号:6944635
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Utilizing Glycosyltransferases for Bioconjugation
-
批准号:8552799
-
项目类别:
-
资助金额:$20.9万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Detection of Specific Glycan Moieties on the Cell Surface
-
批准号:8349512
-
项目类别:
-
资助金额:$18.95万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Oligosaccharide substrate interactions with beta-1,4-Gal
-
批准号:7291793
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Oligosaccharide Substrate and Inhibitor Interactions with beta-1,4-Gal-T1
-
批准号:7732974
-
项目类别:
-
资助金额:$6.55万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Using Glycosyltransferases for Conjugation of Single-Chain Antibodies and Lipids
-
批准号:8157471
-
项目类别:
-
资助金额:$25.49万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
PRINCIPALS OF CONFORMATIONAL ANALYSIS OF CARBOHYDRATES - A TEXT BOOK
-
批准号:6289310
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Structure-Function Studies and Design of Novel Glycosyltransferases
-
批准号:7965164
-
项目类别:
-
资助金额:$25.38万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Using Glycosyltransferases for the Development of Targeted Drug Delivery System
-
批准号:7965699
-
项目类别:
-
资助金额:$20.3万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Using Glycosyltransferases for the Development of Targeted Drug Delivery System
-
批准号:8763229
-
项目类别:
-
资助金额:$17.12万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Structure-Function Studies and Design of Novel Glycosyltransferases
-
批准号:8348931
-
项目类别:
-
资助金额:$28.43万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Utilizing Glycosyltransferases for Bioconjugation
-
批准号:8349131
-
项目类别:
-
资助金额:$23.69万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Using Glycosyltransferases for the Development of Targeted Drug Delivery System
-
批准号:7592951
-
项目类别:
-
资助金额:$8.0万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Using Glycosyltransferases for the Development of Targeted Drug Delivery System
-
批准号:7733240
-
项目类别:
-
资助金额:$7.49万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Oligosaccharide Substrate and Inhibitor Interactions with beta-1,4-Gal-T1
-
批准号:7592633
-
项目类别:
-
资助金额:$15.0万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Structural studies on beta-1,4-Galactosyltransferase fa
-
批准号:7048930
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Using Glycosyltransferases for Conjugation of Single-Chain Antibodies and Lipids
-
批准号:7965701
-
项目类别:
-
资助金额:$25.38万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
Detection of Specific Glycan Moieties on the Cell Surface
-
批准号:8763484
-
项目类别:
-
资助金额:$13.69万
-
财政年份:--
-
负责人:Pradman K Qasba
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: